AI Stock Analysis: Is ZOM a Smart Buy right now?

November 25, 3:42 am

Zomedica Corporation is a veterinary health company that focuses on providing diagnostic and therapeutic solutions for companion animals. Headquartered in the United States, Zomedica aims to make veterinary diagnostics more affordable and accessible through innovative technology and products.

Price & AI Score for ZOM.

Fundamental Analysis

For the last quarter, Zomedica reported revenue of $7M, an increase of 14.12% compared to the previous quarter, and an increase of 10.24% compared to the same quarter last year. This is a positive indication of the company's growth trajectory.

Net income for the last quarter was $6.7M, an increase of 72.02% from the previous quarter. However, compared to the same quarter last year, there was a significant decrease of 1,263.95%, potentially raising concerns about long-term profitability.

EBITDA for the last quarter was $5.8M, an increase of 75.13% from the previous quarter, yet it experienced a decrease of 514.23% compared to the corresponding quarter last year, which may also be a point of concern for investors.

Technical Analysis

Currently, Zomedica's stock price is $0.13, marking an increase of 8.33% from a month ago but a decrease of 27.78% compared to a year ago. These figures suggest a positive short-term trend but raise concerns about its long-term performance.

The stock's Simple Moving Average (SMA10) is $0.13, which is not trending upward compared to the previous SMA10 of $0.13, indicating a potential downward price movement. The Relative Strength Index (RSI) stands at 33.3, suggesting a neutral condition without extreme overbought or oversold signals.

Alternative Data Analysis

From a workforce and employee sentiment perspective, Zomedica has 6 open positions, remaining stable over the last few months, pointing to potential growth and expansion. Employee sentiment is high, with 83% of employees having a positive outlook, and this sentiment has increased by 32% recently, both healthy indicators for company morale and growth.

However, customer acquisition metrics show that Zomedica has an estimated 23,000 visitors to their webpage, which is down by 23% in the last couple of months—an alarming trend as it may signal customer attrition. Customer engagement on social media indicates 8,400 followers on their Twitter page, down by 1% in the last couple of months, suggesting a slight loss of interest.

Finally, AltIndex's AI score for Zomedica, which integrates fundamental, technical, and alternative data analysis, is 69, indicating a buy signal.

Conclusion and Recommendation

In summary, Zomedica shows promising growth in its revenue and positive employee sentiment contributing to a generally healthy operating environment. However, significant concerns exist regarding long-term profitability and customer engagement metrics. Nonetheless, the stock currently holds a "buy" recommendation according to AltIndex's AI score of 69, based on an aggregate analysis of fundamental, technical, and alternative data points.

Disclaimer: This article, generated by an experimental AI tool, is for informational purposes only and not financial advice. Information is based on publicly available data and may not always be accurate or current. Visit ZOM AI Stock Analysis for a more up-to-date analysis.

Get More Insights

Sign up and get access to a personalized dashboard, deeper insights, AI stock picks, stock alerts, weekly newsletter and much more.

About Us

AltIndex revolutionizes investing with advanced alternative data analytics, smart insights, and stock alerts, presented in an easy-to-use dashboard powered by comprehensive company data from across the internet.



App download

Legal Disclaimer
The information provided by AltIndex is solely for informational purposes and not a substitute for professional financial advice. Investing in financial markets carries inherent risks, and past performance doesn't guarantee future results. It's crucial to do your research, consult with financial experts, and align your financial objectives and risk tolerance before investing. AltIndex creators and operators are not liable for any financial losses incurred from using this information. Users should exercise caution, seek professional advice, and be prepared for the risks involved in trading and investing in financial assets, only investing what they can afford to lose. The information in this application, derived from publicly available data, is believed to be reliable but may not always be accurate or current. Users should verify information independently and not solely rely on this application for financial decisions. By using AltIndex, you acknowledge that it doesn't offer financial advice and agree to consult a qualified financial advisor before making investment decisions.

© 2024 AltIndex. All rights reserved.